Although challenging, developing evidence-based approaches to an early and accurate diagnosis of systemic lupus erythematosus is a key approach to preventing disease and lupus-associated morbidity and mortality. Advances in our understanding of preclinical and incomplete lupus erythematosus have enabled the identification of risk factors that may predict disease and the development of potential strategies aimed at primary prevention. Emerging data support the notion that there is a temporal disease progression from initial asymptomatic autoimmunity (preclinical lupus) through early clinical features of the disease (incomplete lupus erythematosus) to finally becoming fully classifiable systemic lupus erythematosus (complete lupus erythematosus). Here, we review the demographic, clinical, biomarker as well as genetic and environmental features that are reported to increase the risk of disease progression. Based on these risk factors, we propose a clinical care pathway for patients with early disease. We envisage that such a pathway, through early identification of disease, may improve patient outcomes, while reducing health care costs. Lupus (2016) 25, 838-849.
Introduction
Systemic lupus erythematosus (SLE) is a heterogeneous disease characterized by wide variations of clinical onset and phenotypes 1 with disease in multiple organ systems, frequently affecting young adults at the peak of their economic productivity. 2, 3 Although improvements in the diagnosis and treatment of SLE have had a remarkable impact on survival and life expectancy, 4, 5 patients can still experience frequent disease flares and develop severe organ involvement and, consequently, incur substantial costs. [6] [7] [8] [9] [10] We posit that by understanding published demographic, clinical, biomarker, genetic and environmental features associated with the onset of SLE, an approach may be developed to case finding of early or incomplete lupus erythematosus (ILE) followed by the implementation of evidencebased strategies to avert, delay or ameliorate pathogenic disease processes. [11] [12] [13] [14] [15] [16] [17] The anticipated outcomes of this approach are to achieve an early diagnosis, to initiate appropriate, evidence-based efficacious interventions to improve outcomes and quality of life and decrease health care costs. CSLE, usually within 5 years of disease onset. 22, 23 In one study, 28 patients with ILE were followed for 10-20 years (mean 13 years) and 57% of them developed CSLE between 1 and 10 years, with a median time to CSLE development of 5.3 years. 24 In a study of 345 ILE patients enrolled in the multicenter Spanish Rheumatology Society SLE Registry (RELESSER), 22 the most common features were a positive ANA in 94.7%, followed by immunological disorder (i.e. anti-dsDNA, anti-Sm, antiphospholipid) in 55.1%, arthritis in 44.2% and hematological abnormalities in 43.7%. In addition, 17.3% had cardiac manifestations, 14.9% had neuropsychiatric symptoms and 6.3% had lupus nephritis. Compared with CSLE, disease activity, damage and severity were lower among ILE patients when adjusted for gender, age at diagnosis and disease duration. Patients that do transition to CSLE may have accrued some irreversible organ damage by the time of a definitive diagnosis. 16 Organ damage was more common in ILE patients of older age and with high systemic lupus erythematosus disease activity index (SLEDAI) scores. 24 There is a need to identify the patients who are most likely to progress to CSLE and hence target therapy to those who are likely to experience the greatest benefit. The first step in identifying such patients is a better understanding of the predictors of disease progression including demographic, clinical, biomarker, genetic and environmental factors. This will aid in the creation and implementation of an accurate and effective clinical care pathway for SLE screening and prevention.
Demographic and clinical features associated with disease progression
Recent studies have identified clinical characteristics that help distinguish ILE patients at risk of developing CSLE. In a retrospective study of 161 ILE patients enrolled in the Brigham and Women's Hospital Lupus Registry, 25 independent predictors of the development of CSLE at initial consultation included oral ulcers (odds ratio (OR) 2.40, 95% confidence interval (CI) 1.03-5.58), persistent proteinuria or urinary cellular casts (OR 16.20, 95% CI 1.63-161.02), and anti-dsDNA (OR 2.59, 95% CI 1. 25-5.35) . It should be noted that in the context of the SLICC criteria, 20 patients with lupus nephritis on biopsy and an ANA or anti-dsDNA could be classified as CSLE. Another study followed a group of 87 ILE patients for 2.2 years and found that malar rash, oral ulcers, anti-dsDNA and decreased C4 were associated with progression to CSLE. 26 A Swedish study of 28 ILE patients also found that malar rash and anti-cardiolipin (aCL) antibodies were predictors of SLE development. 24 Compelling evidence indicates that racial/ethnic minorities such as African-Americans, Asians and Aboriginals have a higher incidence of SLE, have a more severe disease course, develop more endorgan damage and have a higher risk of death than Caucasians. [27] [28] [29] [30] [31] Poverty, lower education, lack of health insurance, poor social support and other socioeconomic disparities are generally more common in these racial/ethnic minorities, and cumulatively influence the course and outcomes of the disease. Some of these issues are discussed later.
Biomarkers
It is well known that certain biomarkers can appear years prior to clinical symptoms and/or the diagnosis of SLE. 12, 16, [32] [33] [34] [35] Autoantibodies and a variety of immune-related and inflammation-related pathways, including complement activation and specific cytokines and chemokines, are thought to be among the first diagnostic clues of disease onset (Table 1, Figure 1 ).
Several longitudinal studies have examined the evolution of autoantibodies in SLE over time. In a seminal study of 130 former military SLE patients whose sera were available from the USA Department of Defense Serum Repository, Arbuckle et al. 32 detected at least one SLE autoantibody before the diagnosis of SLE and before the appearance of the first clinical manifestation in 88.5% (115/130) of subjects. Although the first clinical symptoms manifest on average 1.5 years prior to diagnosis, the mean interval from earliest autoantibodies detected to diagnosis of CSLE was remarkably longer, ranging from 3.68 years for anti-Ro to 0.88 years for anti-U1RNP. ANA (1:120) were present in 78% and, of the ANA subserologies, 55% had anti-dsDNA, 47% anti-Ro60, 34% anti-La, 32% anti-Sm and 26% anti-U1RNP. ANA and anti-Ro60 and anti-SSB/La antibodies were present earlier than anti-Sm and anti-U1RNP antibodies (mean of 3.4 years versus 1.2 years). By comparison, of the 130 matched controls, 3.8% had a single autoantibody detected: 3% anti-dsDNA, 3% anti-SSA/Ro60, 2% anti-RNP, 0% anti-Sm and anti-La. Thus the positive predictive value (PPV) of autoantibodies ranged from 93.8% for anti-SSA/Ro to 100% for anti-Sm, with a mean value of 95.8% for all autoantibodies included in the study. 12 It is important to point out that both the prevalence of autoantibodies and time to antibody positivity may have been underestimated as some of the initial samples were already positive on analysis and, in general, much less sensitive immunoassay technologies were employed at the time of this study.
Anti-cardiolipin antibodies, which are included in the classification criteria of primary antiphospholipid syndrome (APS) 36 and SLE 19 may also be important in case finding. In the same subjects reported by Arbuckle et al. 32 and McClain et al. 37 noted that moderate or high levels of aCL were present in 18.5% of the patients up to 7.6 years before the diagnosis of SLE (mean 3.1 years). Of note, 12 of 24 (50%) of these patients had a venous or arterial thrombotic event or recurrent spontaneous abortion and all but one of these events occurred prior to the diagnosis of SLE. In addition, the aCL-positive patients had a more severe disease, including a higher frequency of renal and central nervous system disease, and thrombocytopenia than SLE patients without aCL. In another study, aCL antibodies antedated the onset of early organ damage in SLE and were the sole independent predictor of disease damage at 5 years. 38 In addition, the presence of aCL may help to predict cases of SLE evolving to secondary APS 39 and identify those who may benefit from aspirin therapy to reduce the risk of thrombotic events. 40 One study reported that primary APS evolving into SLE may be predicted by the presence of anti-nucleosome antibodies. 41 In that study, Abraham et al. 41 followed 18 primary APS patients, nine of which had anti-nucleosome autoantibodies, for up to 11 years. Six of the nine patients developed clinical manifestations of SLE in the follow-up period, compared with none of the patients who did not have detectable anti-nucleosome autoantibodies. Biomarkers predictive of SLE were also studied in patients with undifferentiated connective tissue disease (UCTD). 42 Patients with a homogenous ANA indirect immunofluorescence pattern or with anti-dsDNA, anti-Sm and aCL antibodies were at higher risk of transitioning to CSLE as were those with multiple autoantibodies or multiple clinical features of SLE. 43, 44 Taken together, the results of the studies reviewed above demonstrate the existence of a hierarchy in autoantibody appearance that facilitate SLE case finding through autoantibody testing.
Differences in T-cell subsets have also been shown to predict UCTD patients at risk of transitioning to systemic autoimmune diseases (SARDs, includes SLE, rheumatoid arthritis, mixed connective tissue disease, Sjo¨gren's syndrome or systemic sclerosis). In a prospective, longitudinal study of 51 patients with UCTD, the frequency of circulating Th17 cells were higher in patients who transitioned to SARDs as compared with patients who did not. In addition, the ratio of Th17 to natural regulatory T cells and to type 1 regulatory T cells was also higher in patients who developed a SARD. 45 Dysregulation of interferon (IFN)-alpha (i.e. the IFN signature), may play a key role in SLE-related autoimmunity, [46] [47] [48] [49] where it has been linked to the presence of SLE-related autoantibodies but not to clinical manifestations of disease. It was hypothesized that IFNa may be specially related to the development of autoimmunity. The pathogenic processes linked to IFNa pathways, especially in patients with a prominent IFNa signature, could also be potential therapeutic targets for prevention of progression to clinical disease. [50] [51] [52] [53] [54] Of interest, several susceptibility genes implicated in SLE, such as IRF5, IRF7, IFIH1, STAT4 and TYK2, also map to this pathway. 55, 56 This presents the possibility of using both genomics and proteomics (autoantibodies, interferon signature) as a more powerful way to predict SLE onset but also offers some insight into therapies that could effectively prevent CSLE. Further studies are still needed, however, to determine their clinical utility as biomarkers.
Other serum proteins identified as potential biomarkers for SLE are listed in Table 1 . 49, 57 Additional serum and urine biomarkers predictive of renal involvement are also under investigation. 49, 58, 59 There are some suggestions that with the advent of predictive biomarkers and personalized medicine in SLE, 60 kidney biopsies may become a thing of the past. 61, 62 The findings from these 'omics studies have led to the concept that individuals who develop CSLE have an initial preclinical stage of 'benign' autoimmunity that can progress to a more ominous stage of pathogenic autoimmunity (Figure 1 ). The precise mechanisms leading to tissue injury are presently, however, incompletely understood. A recent review 57 proposed several processes including expansion of autoreactive T cells and B cells, epitope spreading, increases in inflammation, upregulation of signaling molecules, inflammationrelated antigen production and presentation, and physicochemical alterations of autoantibodies rendering them more capable of inducing disease.
Genetic and environmental factors
Most of the known genetic and environmental risk factors were identified through case control studies. 13 In CSLE, there is a 25% concordance rate observed among monozygotic twins compared with 2% in dizygotic twins, 63 and association studies have identified more than 40 candidate genes in SLE. 57 The strongest genetic factors include complement, which is involved in the removal and degradation of anti-DNA-nucleosome complexes. 57 Major histocompatibility complex mutations have also been implicated in facilitating the recognition of self-antigens by T cells leading to autoimmunity in SLE. 57 One of the 'great hopes' for SLE is that genomics will become the leading edge of personalized medicine. 64 Various environmental exposures have been implicated in the induction, acceleration or promotion of flares in SLE, [65] [66] [67] [68] and readers are referred to a special edition of Lupus that focused on this topic. 69 Nevertheless, there are no definitive data that quantify the relative contributions of these environmental risk factors to disease development, onset or flare. 70 Among the environmental agents studied in SLE, cigarette smoke [71] [72] [73] [74] [75] [76] [77] and environmental air pollutants 78, 79 have attracted significant interest. It should be appreciated that the detrimental effects of cigarette smoking also apply to marijuana smoking. [80] [81] [82] Smoking increases disease activity and is reported to interfere with the action of antimalarial drugs. [83] [84] [85] Its main effects occur in the context of HLA-DR3 alleles. 86 Other environmental factors such as silica, [87] [88] [89] [90] as well as industrial pollution and solvents are reported to increase the risk of SLE and may impact disease manifestations, severity and outcomes. 91, 92 Diet and nutritional status may also play a role in the development and progression of SLE. 77, 93, 94 Alcohol intake has been associated with a shortterm increased risk of SLE in genetically susceptible individuals, 95 and may even have a protective effect when taken in moderation, 95,96 but this remains an area of controversy. 74, 97 The role of vitamin D deficiency, and its association with onset or flares of SLE [98] [99] [100] [101] [102] [103] [104] is not clearly established 105 and, likewise, studies evaluating the benefits of vitamin D supplementation on reducing disease activity have been inconsistent.
Excess ultraviolet (UV) radiation exposure may exacerbate pre-existing SLE, but it remains unclear whether UV exposure is a risk factor for the development of SLE. 91, 106, 107 Although experimental studies show a significant immunomodulatory role for UV radiation, 106, 108 particularly in the anti-SSA/Ro60 and anti-dsDNA autoantibody systems, [109] [110] [111] strong epidemiologic data confirming its role in triggering the onset of SLE are still lacking.
Several viruses have also been implicated as factors that influence the development of disease during the preclinical period and possibly represent true triggers of disease. [112] [113] [114] Serological studies in patients with established SLE and ILE point to evidence that infection with the ubiquitous Epstein-Barr virus (EBV) precedes the development of autoantibodies. [115] [116] [117] EBV and other viral antigens are thought to promote the generation of an initial autoimmune response to nuclear autoantigens like SSA/Ro60 118 , SmD1 119 and SmB 0 /B 116 through molecular mimicry, [120] [121] [122] which are subsequently amplified through processes such as epitope spreading or altered infection processes. 118, 123 Other viruses that have been associated with SLE are listed in Table 1 . 13, [112] [113] [114] 124 Of interest, some microbes and viruses were reported to be protective against the development of SLE. This may be related to the 'hygiene hypothesis' and is thought to explain the higher incidence of SLE in developed countries where there is an improvement in hygiene and an absence of certain microbes. 125 Mu et al. 125 identified hepatitis B virus (HBV) as a protective factor in Chinese SLE patients (2.5% of SLE patients were found to be positive for the HBV-core antibody, compared with 10.7% of normal controls). Positive Helicobacter pylori serology may also be associated with a decreased risk of early onset SLE in African-Americans. 126 In murine studies, pathogenic microbes such as Toxoplasma gondii, 127 Plasmodium chabaudi 128 and lactate dehydrogenase elevating virus were associated with a decreased severity of SLE. 129 Certain drugs, biological therapeutics and drugrelated factors are an important consideration in the development of SLE. [130] [131] [132] [133] Antibiotics (most commonly sulfa, tetracycline and penicillin-related antibiotics), which can alter the gut microbiome, are known triggers of SLE flares. 125 Other drugs commonly known to induce a lupus-like disease include procainamide, hydralazine, quinidine and TNF alpha blockers. 57, 133 Strategies for SLE prevention: towards a clinical care pathway While the prevention of SLE has not achieved mainstream status in rheumatology practices, there are emerging approaches and paradigms that consider the reality of predicting and preventing disease. [11] [12] [13] [14] A clinical care pathway is a structured plan of care (often multidisciplinary in nature) that puts evidence-based guidelines into practice using a plan, algorithm or protocol to guide care with the aim of standardizing care for a defined population (reviewed in Kinsman et al.). 134 Ideally, a clinical care pathway is based on best practices as defined by high quality clinical guidelines. Unfortunately, the approach to ILE is not included in current guideline recommendations for SLE, which focuses on well-defined disease states; [135] [136] [137] [138] therefore designing a clinical care pathway is challenging. Nonetheless, we posit that ILE may be a time to intervene potentially to delay the onset of clinical disease, reduce the burden of disease or even perhaps prevent disease progression and immune dysregulation that leads to CSLE 14, 139 ( Figure 2) .
The proposed components of a clinical care pathway for ILE would require further validation prior to implementation, but we outline a strategy for evaluation and management of this population ( Figure 2) . As with CSLE, ILE may be similarly heterogeneous and we suggest an individualized approach to management based on specific patient manifestations of disease, while considering patient preferences for investigation and treatment. It should also be recognized that ILE may evolve into another connective tissue disease that would potentially warrant a different approach to that outlined below.
When considering a clinical care pathway for ILE, two clinical subsets of patients need to be considered: one for patients with preclinical states (e.g. patients with serological and minor laboratory abnormalities) and one for patients with clinical manifestations of disease who do not yet fulfill ACR or SLICC criteria for SLE. Below we describe clinical pathways to approach these two scenarios.
Preclinical SLE
Population-based screening for SLE is currently not recommended; 140, 141 however, ANA testing is commonly done in many primary care settings for patients with musculoskeletal or other complaints, and a positive test frequently prompts a rheumatological referral. 35, 142, 143 Dating back to the introduction of ANA and ENA profile testing, these tests can contribute to the diagnosis of SLE from perspectives of pretest probability, likelihood ratios, negative predictive value and other considerations. 144 Of note, ANA positivity is also a highly frequent feature of ILE. 14, 16 As in a recently described template and economic analysis, patients who are 'incidentally' found to have a clearly positive ANA (i.e. titer >1:80) should have a complete history and physical exam to evaluate for signs and symptoms of disease, and routine testing for a complete blood count, serum creatinine and liver enzymes as well as a urinalysis, C3, C4 testing, ENA panel, anti-dsDNA and anti-phospholipid antibody screening. 35 If the history and physical exam are not suggestive of clinical disease, and laboratory investigations show only an isolated, low-titer positive ANA, the patient may be returned to primary care after education about signs and symptoms to watch out for and for routine monitoring in primary care. Certain subsets of patients may warrant ongoing specialist follow-up including individuals with a family history of lupus or individuals with an isolated high titer ANA from high-risk ethnic groups, as outlined above. Although the economics of this approach have not been evaluated, compared with the health care costs of CSLE, this may be economical. The human clinical resources (specialists and para-health assistants, clinical time and even specialists more focused and trained in preventative medicine) needed for such an approach must be more clearly elucidated. 145 If additional preclinical features are uncovered (e.g. additional positive serology and persistently low white blood cell count), the patient warrants clinical follow-up on a more regular basis (e.g. every 6-12 months) to monitor for disease progression, as this usually occurs early, with a median time of 5.3 years. 24 Hence, the frequency of screening for disease may be extended after 5 years, 24 although evidence suggests that this population may have mild disease, 26, 146 and a less rigorous follow-up protocol may also be reasonable. All patients in this arm of the clinical pathway warrant education about signs and symptoms of SLE, and patients should be provided information about who to contact should their clinical status change and a mechanism for a rapid reassessment if disease progresses. Further study is warranted to determine if additional preventive strategies such as hydroxychloroquine are safe 147, 148 and cost effective in this population.
Consideration should also be given to providing these patients with information about smoking cessation and sun care. Based on the discussion above, some areas of intervention and behaviour modification that might become key to limiting disease progression are outlined in Figure 2 .
Clinical symptoms/signs that do not fulfill criteria for CSLE
Patients who have symptoms/signs but do not fulfill criteria for CSLE (e.g. isolated organ involvement of skin and joints) warrant a complete work-up (history, physical exam, serological and laboratory testing). These individuals should be followed closely after presentation to monitor for new organ involvement. The frequency of laboratory and clinical assessment in this population has not been optimally determined and we suggest an individualized approach based on additional risk factors; for example, individuals of high-risk ethnicities (e.g. African-American, Hispanic, Asian and North American indigenous populations) [28] [29] [30] [31] or with a positive family history, highly elevated anti-dsDNA and/or anti-chromatin, antiC1Q and hypocomplementemia, or severe single organ involvement may warrant close clinical follow-up.
In patients with ILE, antimalarial therapy has been shown to delay the onset of CSLE and also decrease the repertoire and expression levels of autoantibodies present at the time of diagnosis. 16, [149] [150] [151] In a retrospective study of 130 US military personnel who later met the ACR SLE classification criteria, hydroxychloroquine delayed the onset of complete SLE and reduced the number of SLE autoantibodies present at and after SLE diagnosis. 152 In addition, specific organ involvement may warrant additional treatment depending on the severity of manifestations, and such treatment is similar to treatment offered in the context of CSLE, while maintaining a vigil for side effects. As with preclinical SLE patients, counseling about sun avoidance and smoking cessation should be components of prevention therapy.
Although the approaches described above are clinically sensible, the optimal follow-up approach and possible preventive strategies for these patients has, to date, not been clearly determined and further evaluation of these proposed clinical pathways is warranted. Areas for further study include appropriate and cost-effective screening strategies for SLE in high-risk populations and novel predictive tools and/or biomarkers to better identify individuals at risk of disease progression better to tailor follow-up protocols.
The economics of SLE
SLE is a costly disease and we posit that outcomes could be improved and some costs averted by earlier diagnosis and the implementation of preventive strategies (as outlined in our care pathway) in selected high-risk populations. However, this approach requires further study. Below, we briefly review the economic costs of CSLE and how they may be altered by early diagnosis and treatment and preventive measures.
The direct (value of health care resources used) and indirect (value of diminished productivity) costs of CSLE have been well documented, 153 and have been shown to be highest in those with higher disease activity, 154, 155 frequent disease flares [156] [157] [158] [159] and with renal and central nervous system involvement. [6] [7] [8] 10, [160] [161] [162] Based on health insurance claims, the annual per patient direct costs for CSLE were estimated to range as high as $71,334.00 (2015 US dollars) in those with lupus nephritis. 6 A systematic review from 2000 to 2009 demonstrated that most SLE direct costs were related to inpatient (16-50%) and outpatient (24-56%) services, followed by medications (19-30%). 163 Due to the chronic, unpredictable and systemic nature of CSLE, patients often have reduced ability to perform remunerated work, care for their dependents and engage in other unpaid work. Hence, the resulting indirect costs can exceed direct costs by two to four-fold. 153, 160, 161, 164, 165 Similar to direct costs, indirect costs are also influenced by increased disease activity, and renal and neuropsychiatric involvement. In addition, jobrelated factors such as inflexibility in working hours and physically and cognitively demanding jobs contribute to diminished productivity. 166 Renal involvement, one of the most expensive complications of CSLE, has been demonstrated to develop very early in the disease course. 167 The SLICC assembled an inception cohort of 1827 patients enrolled within 15 months of disease onset, with mean disease duration at enrolment of 0.5 years. A total of 38.3% of the cohort developed nephritis over a mean follow-up of 4.6 years, but 80% of those with lupus nephritis actually had it diagnosed at enrolment. Hence, lupus nephritis is frequently present at disease onset and studies have shown that earlier diagnosis and treatment are likely to contribute to improved outcomes 168 and, by extension, reduced health care costs. 169 It is also anticipated that if the preventive strategies discussed in the preceding section were effective in reducing the likelihood of progression from ILE to CSLE, there would be substantial cost savings. However, it is not yet possible to estimate the economic effects of such preventive strategies, as their efficacy and costs have not been evaluated in large-scale trials and the evolution and costs of ILE have not been studied in large cohorts. Interventions, which are evaluated as potential preventive strategies, could have several effects: (a) completely halt the progression from ILE to CSLE; (b) modulate the expression of CSLE into a less severe phenotype; (c) delay the evolution from ILE to CSLE by months to years; (d) not alter the progression, (e) hasten the progression; or (f) modify the transition of ILE into a non-CSLE SARD. Nevertheless, despite the current lack of economic evidence for preventive strategies, there is certainly a sufficient body of clinical literature to support efforts to make an earlier diagnosis of SLE and design therapeutic and intervention paradigms that focus not only on intent to treat, but also on intent to prevent the disease. 35 
Conclusions
There is emerging evidence and paradigms that support the benefits of treating preclinical lupus and that ILE progresses to CSLE. The demographic, clinical, biomarkers, genetic and environmental factors that may predict who is at greatest risk of progression, and the possible clinical care pathways have been discussed along with a consideration of pharmacological therapy that might be implemented. SLE patients, particularly those with lupus nephritis and neuropsychiatric disease, can experience considerable morbidity and incur substantial direct and indirect costs. We have attempted to make a case for earlier diagnosis and intervention and, perhaps even disease prevention as an approach to improving outcomes, with a likely attendant reduction in both direct and indirect costs. As potential preventive therapies are trialed and data on the trajectories and costs of ILE become available, we will be able to determine if the costs of such approaches are commensurate with their health and economic benefits.
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